Viable Osteochondral Allograft for the Treatment of a Full‐Thickness Cartilage Defect of the Patella

Jarret M. Woodmass; Heath P. Melugin; Isabella T. Wu; Daniël B.F. Saris; Michael J. Stuart; Aaron J. Krych

doi:10.1016/j.eats.2017.06.034

journal article Open Access Sep 25, 2017

Viable Osteochondral Allograft for the Treatment of a Full‐Thickness Cartilage Defect of the Patella

Jarret M. Woodmass Heath P. Melugin Isabella T. Wu Daniël B.F. Saris Michael J. Stuart

Aaron J. Krych

Arthroscopy Techniques Vol. 6 No. 5 · Wiley

View at Publisher Save 10.1016/j.eats.2017.06.034

Abstract

Abstract

Isolated cartilage defects can lead to significant pain and disability, prompting the development of a number of options for restorative treatment. Each method has advantages and limitations, and no single technique has gained widespread use. We present a technique for implantation of a cryopreserved osteochondral allograft (Cartiform) for the treatment of full‐thickness cartilage defects. Cartiform is a cryopreserved osteochondral allograft composed of chondrocytes, chondrogenic growth factors, and extracellular matrix proteins. This implant allows for regenerative treatment of full‐thickness cartilage lesions in a single surgical procedure.

Technique Video

video

See video under supplementary data.

Topics

No keywords indexed for this article. Browse by subject →

References

17

[1]

10.1016/s0749-8063(97)90124-9

[2]

KrychAJ PareekA KingAH JohnsonNR Stuart MJ Williams RJ 3rd.Return to sport after the surgical management of articular cartilage lesions in the knee: A meta‐analysis.Knee Surg Sports Traumatol ArthroscAugust 18 2016. [Epub ahead of print.] 10.1007/s00167-016-4262-3

[3]

10.2106/jbjs.i.00895

[4]

10.1177/1941738113508917

[5]

10.1177/0363546512441586

[6]

10.1177/0363546508330137

[7]

10.1097/00003086-200110001-00032

[8]

10.2106/00004623-200710000-00002

[9]

10.1056/nejm199410063311401

[10]

Osiris Therapeutics I.Characterization of Cartiform® viable osteochondral allograft. Cartiform White Paper 2015.

[11]

Osiris Therapeutics I.Cartiform® retains endogenous viable cells after two years storage at –80°C. Cartiform White Paper 2015.

[12]

Osiris Therapeutics I.Cartiform promotes mesenchymal stem cell migration and chondrogenesis. Cartiform White Paper 2015.

[13]

10.1097/00003086-200208000-00020

[14]

10.2106/00004623-200603000-00006

[15]

10.1155/2015/617365

[16]

10.1186/s13018-015-0209-5

[17]

10.1007/s12178-012-9132-0

Metrics

16

Citations

17

References

Details

Published: Sep 25, 2017
Vol/Issue: 6(5)
License: View

Authors

J

Jarret M. Woodmass